SAN DIEGO - AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company currently trading near its 52-week low at $12.38, announced significant findings from their Phase 2b RENOIR trial for ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Anaptys Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

AnaptysBio (ANAB) stock climbs as its antibody therapy rosnilimab meets key goals in mid-stage rheumatoid arthritis trial, ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...

AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $7.92 ...

In other AnaptysBio news, Director Ecor1 Capital, Llc bought 6,646 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was acquired at an average price of $12.95 ...

After hours: 7:50:06 pm GMT-5 ...

After hours: February 7 at 7:23:36 PM EST ...